Brief: Inventiva H1 Net Operating Loss Widens To 23.6 Million Euros

Inventiva SA

21/09/2021 07:54

Sept 21 (Reuters) - INVENTIVA SA  IVAA.PA :
    * PUBLISHED ON MONDAY 2021 FIRST HALF FINANCIAL RESULTS AND
PROVIDES A CORPORATE UPDATE
    * H1 REVENUES EUR 139,000 VS EUR 161,000 YEAR AGO 
    * H1 NET OPERATING LOSS EUR 23.6 MLN VS LOSS OF EUR 15.7 MLN
YEAR
AGO 
    * H1 NET LOSS FOR THE PERIOD EUR 23.1 MLN VS LOSS OF EUR
15.7 MLN
YEAR AGO
    * AS OF JUNE 30, 2021, CASH AND CASH EQUIVALENTS EUR 93.6
MLN VS
EUR 105.7 MLN AT END-DEC
    * CASH RUNWAY WILL ALLOW COMPANY TO FUND ITS OPERATIONS
THROUGH Q3
2022
    * INITIATION BY ABBVIE OF THE PHASE IIB CLINICAL TRIAL WITH
CEDIROGANT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS PLANNED
FOR NOVEMBER 2021
    * STRATEGY UPDATE ON DEVELOPMENT OF ODIPARCIL PLANNED FOR
2022 VS
H2 2021 AS PREVIOUSLY ANTICIPATED
    * PUBLICATION OF RESULTS OF PHASE II CLINICAL TRIAL
EVALUATING
LANIFIBRANOR FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
(NAFLD) IN PATIENTS WITH TYPE 2 DIABETES (T2DM) PLANNED FOR H1
2022

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE2SQQKG
    
 Further company coverage:  IVAA.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))